{'fraction_non_alphanumeric': 0.03375, 'fraction_numerical': 0.0225, 'mean_word_length': 5.209302325581396, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience

Background: Severe 5-FU toxicity in adjuvant therapy of colorectal cancer may require change of therapy. We retrospectively explored the safety and efficacy of adjuvant raltitrexed in patients intolerant of 5-FU. Methods: Over a 5 year period, patients who received 5-FU and subsequent raltitrexed therapy were identified. Results: There were 44 patients, (39 stage III). Median number of prior 5-FU cycles was 2. Three year relapse free and overall survival proportions for stage III patients were 70.8% and 83.6%, respectively. Conclusions: Raltitrexed adjuvant therapy can be given safely and effectively in patients where further 5-FU is contraindicated.